ClinicalTrials.gg
Enrolling by invitationNCT06191094Updated Jun 1, 2026

Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy

A Phase 4 interventional study of Faricimab Injection and sham treatment in Diabetic Retinopathy and Vitreous Hemorrhage Due to Diabetes Mellitus, sponsored by University of Colorado, Denver. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by University of Colorado, Denver · Phase 4, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 267 studies in Diabetic Retinopathy with a site in United States — 36 open to participants now, 54 under way, 6 of them phase 3. Diabetic Retinopathy · United States.

Planned enrollment
87th of 196
100 · median 72
Started
2024
with 10 others
Phase 4
20 of 267
6 open now
Primary completion
2026-12
later than 13 of 52 live
Registered
226th of 267
by date

Among the 267 studies in Diabetic Retinopathy with a site in United States, this one is the 87th largest by planned enrollment of the 196 interventional ones that give a count, is one of 11 that started in 2024, is one of 20 in phase 4, reaches primary completion later than 13 of the 52 other live ones, and was the 226th registered.

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

36 of the 267 studies in Diabetic Retinopathy with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 267 studies in Diabetic Retinopathy with a site in United States, or all of them as a file.
02

Study summary

In this phase IV, randomized, double-masked, sham-controlled study the investigators hope to determine the efficacy in peri-operative faricimab (Vabysmo) compared to sham in limiting complications from pars plana vitrectomy for diabetic vitreous hemorrhage with or without tractional retinal detachments.

03

Conditions studied

  • Diabetic Retinopathy
  • Vitreous Hemorrhage Due to Diabetes Mellitus

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must meet the following criteria for study entry:

  • Signed Form
  • Age ≥ 18 years at time of signing Informed Consent Form
  • Ability to comply with the study protocol, in the investigator's judgment
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use as defined below:

    • Women must remain abstinent or use contraceptive methods with a failure rate of \<1% per year during the treatment period and for 3 months after the final dose of the study drug.
    • A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and is not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and/or uterus) or another cause as determined by the investigator (e.g., Müllerian agenesis).
    • Examples of contraceptive methods with a failure rate of \< 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.
    • The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.

Ocular inclusion criteria for study eye:

● Patients diagnosed with non-clearing vitreous hemorrhage with or without tractional retinal detachment secondary to proliferative diabetic retinopathy and undergoing pars plana vitrectomy

Exclusion criteria

Exclusion Criteria:

General:

Patients who meet any of the following general exclusion criteria will be excluded from study entry:

  • Any known to any of the components in the faricimab injection
  • Any known hypersensitivity to any dilating eye drops, disinfectants (e.g., iodine), or any of the anesthetics and antimicrobial preparations used during the study
  • History of other diseases, other non-diabetic metabolic dysfunction, physical examination finding, or historical or current clinical laboratory finding giving reasonable suspicion of a condition that contraindicates the use of the faricimab or that might affect interpretation of the results of the study or renders the patient at high-risk for treatment complications, in the opinion of the investigator
  • Pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the final dose of faricimab Women of must have a negative urine pregnancy test result at baseline prior to initiation of dosing of faricimab/sham and a negative urine pregnancy test at post-op Week 1 prior to dosing of faricimab/sham

Ocular exclusion criteria for study eye:

Patients who meet any of the following exclusion criteria for the study eye will be excluded from study entry:

  • Any ocular anti-VEGF treatment within 3 months prior to Day 1 (Baseline) in the study eye
  • Vitreous hemorrhage or tractional retinal detachment suspected due to cause other than diabetic retinopathy
  • Any glaucoma surgery in the study eye prior to the Day 1 (Baseline) visit
  • History of vitreoretinal surgery/pars plana vitrectomy, corneal transplant, or radiotherapy in study eye
  • Uncontrolled glaucoma (e.g., progressive loss of visual fields or defined as intraocular pressure (IOP) ≥25 mmHg at the Day 1 (Baseline) visit despite treatment with anti-glaucoma medication)
  • Any history of idiopathic, infectious, or noninfectious uveitis
  • Any current or history of ocular disease other than diabetic retinopathy that may confound assessment of the macula or affect central vision (e.g., age-related macular degeneration, retinal vein occlusion, angioid streaks, histoplasmosis, active or inactive cytomegalovirus retinitis, pathological myopia, retinal detachment, macular traction, retinal embolus, macular hole)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Faricimab injection

    Patients will be randomized 2:1 to receive either farcimab (6 mg from 0.05 mL of a 120 mg/mL) or sham injection. The 6-mg dose of faricimab will be administered by IVT at the study site to patients. A specified filter needle must be used for each dose preparation of faricimab according to the instructions provided in the Investigator's Brochure and package insert. No other material than specified should be used. Vials of faricimab drug product are for a single-dose only (one injection preparation per patient per eye). Vials used for one patient must not be used for any other patient. Partially used vials, remaining faricimab drug product, as well as administration material must not be reused.

    Drug: Faricimab Injection

  • Sham comparator
    Sham injection

    Patients will be randomized 2:1 to receive either farcimab (6 mg from 0.05 mL of a 120 mg/mL) or sham injection. The sham procedure mimics an intravitreal injection of faricimab except that the blunt end of an empty syringe is pressed against an anesthetized eye instead of a needle attached to a faricimab-filled syringe.

    Drug: sham treatment

Interventions

  • DrugFaricimabStudies of FaricimabFaricimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pre-operative injection of bevacizumab appears to have mixed results in lowering post-operative vitreous hemorrhage. One potential reason is due to aspiration and removal of medication in the vitreous humor at the time of pars plana vitrectomy leading to less than anticipated results in controlling neovascularization and vitreous hemorrhage post-operatively. To avoid attenuation of our desired effect we plan to repeat faricimab injection post-operatively around week one.

    Also known as: Vabysmo

  • Drugsham treatment

    Patients will be randomized 2:1 to receive either faricimab (6 mg from 0.05 mL of a 120 mg/mL) or sham injection

06

What researchers measure

Primary outcomes

  1. Rates of post-operative vitreous hemorrhage

    Following treatment and surgery, the development of vitreous hemorrhage will be quantified and evaluated.

    Time frame: 6 months

Secondary outcomes

  1. BCVA outcomes

    Vision will be tested following treatment and surgery on the Snellen Chart, with or without correction as indicated.

    Time frame: 6 and 12 months

  2. Rates of re-operation for non-clearing vitreous hemorrhage

    Following treatment and surgery, if re-operation for non-clearing vitreous hemorrhage is indicated, this will be track and quantified.

    Time frame: 6 and 12 months

  3. Rate of post-operative epiretinal membrane formation.

    Following treatment and surgery, the duration of time if a patient was to develop an epiretinal membrane will be quantified and evaluated.

    Time frame: Through study completion, an average of 1 year

  4. Rate of post-operative rhegmatogenous or tractional retinal detachment.

    Following treatment and surgery, the duration of time if a patient was to develop a rhegmatogenous or tractional retinal detachment will be quantified and evaluated.

    Time frame: Through study completion, an average of 1 year

  5. Duration of operative time.

    The official duration of surgical time will be quantified and evaluated.

    Time frame: intra-operatively

  6. Number of endodiathermy use exchanges intra-operatively.

    At the time of surgery, the number of endodiathermy use exchanges will be counted and evaluated.

    Time frame: intra-operatively

  7. Number of retinal breaks intra-operatively.

    At the time of surgery, the number of retinal breaks intra-operatively will be counted and evaluated.

    Time frame: intra-operatively

  8. Number of patients with intra-operative bleeding

    At the time of surgery, the number of patients who experience intra-operative bleeding will be counted and evaluated.

    Time frame: intra-operatively

07

Study locations

1 site
  • Sue Anschutz-Rodgers Eye Center
    Aurora, Colorado 80045, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.

Of 32 phase 4 interventional studies under Diabetic Retinopathy, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's planned 29 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2023
First posted
Jan 5, 2024
StartActual
Jul 12, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Jan 2028
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06191094
Responsible party
Sponsor
First posted
Jan 5, 2024
Start date
Jul 12, 2024
Primary completion
Dec 2026 (estimated)
Completion
Jan 2028 (estimated)
Last update
Jun 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Faricimab

Start the discussion